跳至主要内容
临床试验/NCT02053220
NCT02053220已完成1 期

A Phase 1 Clinical Study of Intra-tumoural Injection or Intravenous Infusion of a Group B Oncolytic Adenovirus (ColoAd1) in Patients With Cancer Who Are Candidates for Resection of Primary Tumour

Akamis Bio2 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2013年6月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
Akamis Bio
入组人数
17
试验地点
2
主要终点
Composite measure of viral delivery and spread

研究概览

简要总结

To assess the pattern of ColoAd1 viral delivery and viral expression within colon tumour tissue when administered by intra-tumoural injection or within colon, non-small cell lung, bladder and renal cell tumour tissues following ColoAd1 administration by intravenous infusion.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Composite measure of viral delivery and spread

时间窗: Up to Day 25

To assess the pattern of viral delivery and viral spread of ColoAd1 within tumour tissue when administered either by intra-tumoural injection or by intravenous infusion. Viral delivery and spread will be measured by immunohistochemical staining for ColoAd1 in tumour sections taken from patients. Presence of virus will also be detected by qPCR analysis of tumour tissue.

次要结局

未报告次要终点

研究者

发起方
Akamis Bio
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验